DB:1OT

Stock Analysis Report

Executive Summary

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Ovid Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1OT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

1OT

3.3%

DE Biotechs

2.2%

DE Market


1 Year Return

32.6%

1OT

-11.2%

DE Biotechs

-17.2%

DE Market

Return vs Industry: 1OT exceeded the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: 1OT exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

1OTIndustryMarket
7 Day0%3.3%2.2%
30 Day-20.3%-6.5%-15.7%
90 Day-44.9%-23.1%-24.0%
1 Year32.6%32.6%-11.0%-11.2%-14.9%-17.2%
3 Yearn/a14.9%13.6%-16.4%-23.3%
5 Yearn/a-8.0%-10.3%-16.5%-27.8%

Price Volatility Vs. Market

How volatile is Ovid Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ovid Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1OT (€2.28) is trading below our estimate of fair value (€75.47)

Significantly Below Fair Value: 1OT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1OT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1OT is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1OT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1OT is good value based on its PB Ratio (2.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Ovid Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

52.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1OT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1OT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1OT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1OT's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 1OT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1OT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Ovid Therapeutics performed over the past 5 years?

-24.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1OT is currently unprofitable.

Growing Profit Margin: 1OT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1OT is unprofitable, and losses have increased over the past 5 years at a rate of -24.9% per year.

Accelerating Growth: Unable to compare 1OT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1OT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 1OT has a negative Return on Equity (-86.34%), as it is currently unprofitable.


Next Steps

Financial Health

How is Ovid Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 1OT's short term assets ($79.8M) exceed its short term liabilities ($10.5M).

Long Term Liabilities: 1OT's short term assets ($79.8M) exceed its long term liabilities ($286.6K).


Debt to Equity History and Analysis

Debt Level: 1OT is debt free.

Reducing Debt: 1OT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 1OT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 1OT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1OT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 1OT has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -35.8% each year.


Next Steps

Dividend

What is Ovid Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1OT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1OT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1OT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1OT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1OT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Jeremy Levin (66yo)

5s

Tenure

US$2,661,538

Compensation

Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 and serves as its Executive Director. From 1996 to 2000, Dr. Levin has mor ...


CEO Compensation Analysis

Compensation vs Market: Jeremy's total compensation ($USD2.66M) is above average for companies of similar size in the German market ($USD731.58K).

Compensation vs Earnings: Jeremy's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jeremy Levin
Chairman & CEO5yrsUS$2.66m8.66% $12.3m
Amit Rakhit
President0.25yrUS$1.55m0.019% $26.6k
Matthew During
Founder & Chairman of Scientific Advisory Board0.83yrUS$1.39m7.87% $11.2m
Timothy Daly
Executive Vice President of Finance0.25yrno datano data
Lora Pike
Senior Director of Investor Relations & Public Relationsno datano datano data
Thomas Perone
Senior VP1yrno datano data
Suzanne Wakamoto
Senior Vice President of Human Resourcesno datano datano data
Anna Kazanchyan
Senior Vice President of Product Developmentno datano datano data
Dirk Haasner
Senior Vice President of Manufacturing & CMC QA4yrsUS$1.18mno data
Claude Nicaise
Head of Strategic Orphan Regulatory Affairsno datano datano data

1.0yrs

Average Tenure

54yo

Average Age

Experienced Management: 1OT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jeremy Levin
Chairman & CEO5yrsUS$2.66m8.66% $12.3m
Matthew During
Founder & Chairman of Scientific Advisory Board0.83yrUS$1.39m7.87% $11.2m
Douglas Williams
Independent Director4.17yrsUS$101.07k0.0091% $13.0k
Barbara Duncan
Independent Director2.67yrsUS$91.07kno data
Bart Friedman
Lead Independent Directorno dataUS$88.57kno data
Jacqueline French
Member of Scientific Advisory Board3.17yrsno datano data
Howard Federoff
Member of Scientific Advisory Boardno datano datano data
Karen Bernstein
Independent Director4.42yrsUS$101.07k0.037% $52.0k
Daniel Geschwind
Member of Scientific Advisory Board3.83yrsno datano data
David Eidelberg
Member of the Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

64yo

Average Age

Experienced Board: 1OT's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.2%.


Top Shareholders

Company Information

Ovid Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ovid Therapeutics Inc.
  • Ticker: 1OT
  • Exchange: DB
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$157.566m
  • Listing Market Cap: US$142.109m
  • Shares outstanding: 54.71m
  • Website: https://www.ovidrx.com

Number of Employees


Location

  • Ovid Therapeutics Inc.
  • 1460 Broadway
  • Suite 15044
  • New York
  • New York
  • 10036
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OVIDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2017
1OTDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2017

Biography

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 00:16
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.